New prostate cancer drug shows promise in early trial
NCT ID NCT04662580
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The main goal is to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARX517 (a drug that targets prostate cancer cells and delivers a toxin to kill them)
What this could lead to
If it works, this could point toward a new treatment option for men with advanced prostate cancer that has spread.
What could go wrong
This is an early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work well or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
GU Research Network
Omaha, Nebraska, 68130, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202-5116, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center at Mission Bay
San Francisco, California, 94143-2350, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California, Los Angeles School of Medicine
Los Angeles, California, 90095-3000, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-5000, United States
-
University of Washington
Seattle, Washington, 98101, United States
-
Washington University St. Louis School Medicine Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical College
New York, New York, 10021-5663, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States